Brief: Caribou Biosciences Selects ROR1 As Target For CB-020

Caribou Biosciences

12/12/2022 13:34

Dec 12 (Reuters) - Caribou Biosciences Inc  CRBU.O :
    * CARIBOU BIOSCIENCES SELECTS ROR1 AS THE TARGET FOR CB-020,
AN
IPSC-DERIVED ALLOGENEIC CAR-NK CELL THERAPY

Source text for Eikon:  ID:nGNX5dVZPr 
Further company coverage:  CRBU.O 
 ((Reuters.Briefs@thomsonreuters.com;))